Le Lézard
Classified in: Health, Business
Subjects: CON, OTC

MYM Announces Non-Brokered Financing


VANCOUVER, British Columbia, Sept. 26, 2017 /PRNewswire/ -- MYM Nutraceuticals Inc., (CSE: MYM) (the "Company" or "MYM") (MYM.CN) is pleased to announce a non-brokered private placement of up to 6,000,000 units at a price of CAD$0.50 per unit.

Each unit will consist of one common share and one transferable share purchase warrant. Each whole warrant will entitle the holder to acquire one additional common share exercisable for a period of twelve months following the closing of the private placement at a price of CAD $1.00 per warrant share. 

The private placement is subject to the approval of the Canadian Securities Exchange and the securities will be subject to a four month and one day hold period under securities laws. 

The Company intends to use the net proceeds from the private placement for general working capital and corporate purposes.

About MYM

MYM Nutraceuticals Inc. is an innovative company focused on acquiring Health Canada licenses to produce and sell high-end organic medicinal cannabis supplements and topical products.  To ensure a strong presence and growth potential within the industry, MYM is actively looking to the acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors.  MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE: MYM) (OTC:MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).

ON BEHALF OF THE BOARD

Rob Gietl, CEO
MYM Nutraceuticals Inc.
http://www.mymarijuana.ca

This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on http://www.sedar.com.

This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.

Investor Relations: +1-855-696-2261

SOURCE MYM Nutraceuticals Inc.


These press releases may also interest you

at 16:35
Bristol Myers Squibb today announced the Phase 3 CheckMate -73L trial did not meet its primary endpoint of progression-free survival (PFS) in unresectable, locally advanced stage III non-small cell lung cancer (NSCLC). CheckMate -73L evaluated...

at 16:35
Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung...

at 16:35
Merrimack Pharmaceuticals, Inc. ("Merrimack" or the "Company") announced that the stockholders at a Special Meeting held today overwhelmingly approved adopting a Plan of Dissolution. Following that announcement, the Board of Directors declared a...

at 16:15
The Honourable Jean-Yves Duclos, MP for Québec and Minister of Public Services and Procurement, on behalf of the Honourable Mark Holland, Minister of Health, and  the Honourable Carla Qualtrough, Minister of Sport and Physical Activity, will announce...

at 16:15
Chemistree Technology Inc. and (the "Company" or "Chemistree"), announces that is has completed the previously announced restructuring transaction (the "Restructuring Transaction") to settle $6,668,000 in principal amount of outstanding 10% senior...

at 16:15
Edesa Biotech, Inc. , a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and six months ended March 31, 2024 and provided an...



News published on and distributed by: